NWBO: Once In A Decade Best Stock Investment -- Regulatory Approvals Coming! [Dec10, 2022 在第一页加了中文简述]

Henri 说:
請問 for NWBO case,
如果有BO announcement, all shorts need to cover?
但如果是partnership announcement, 那就不一定需要cover shorted shares ？
点击展开...
BO, yes.
Partnership deal, depend on the deal's term particularly with whom the deal is signed, and also the carrying cost of the shorted shares, or the will and expectation of the short (naked). If the shorts also realize the trend has finally turned and the share price can only go up, there will be a short squeeze with lots of margin calls (the shorts will be forced to cover).

Under any circumstances, when the price goes up substantially and the shorts have no way to bring it down via short selling including naked selling because the demand is higher than what they can sell. There won't be any other way but covering and forced covering for the shorts -- squeeze.

In my mind, we will have one down the road, just a matter of in what magnitude!

GL
 
GlobeCitizen 说:
BO, yes.
Partnership deal, depend on the deal's term particularly with whom the deal is signed, and also the carrying cost of the shorted shares, or the will and expectation of the short (naked). If the shorts also realize the trend has finally turned and the share price can only go up, there will be a short squeeze with lots of margin calls (the shorts will be forced to cover).

Under any circumstances, when the price goes up substantially and the shorts have no way to bring it down via short selling including naked selling because the demand is higher than what they can sell. There won't be any other way but covering and forced covering for the shorts -- squeeze.

In my mind, we will have one down the road, just a matter of in what magnitude!

GL
点击展开...
So in a BO case, it’s very possible SP can be much higher than the BO price - at least until all shorted shares are covered?
 
Henri 说:
So in a BO case, it’s very possible SP can be much higher than the BO price - at least until all shorted shares are covered?
点击展开...
Yes, definitely. As a matter of fact, most stocks which experienced a major short squeeze would see its price fall back to earth (normal ranges) from heaven after initial price hikes, either for days or even weeks. It's also depend on at what stage of the short squeeze takes place, if it takes place on a major achieved milestone, the price may shoot higher and then fall back some, which may follow with gradual increase on expectation of other milestones to be achieved.

In case of a BO, yes definitely the price will go higher than the BO price, and even much higher with a squeeze.

BTW, there are other events which can also trigger a squeeze, such as uplisting to NASDAQ or NYSE.
 
A close not as strong as expected.

1670885753021.png
 
Traders exited disappointed at no news (self imposed expectation with some reasoning re ASM on 30 Dec). News outlets most shun any OTC/Penney stocks. Plus the general market just had a reality check as FED Powell spelled no ambiguity re rates. Here you go the depressed price.

1671199281395.png
 
看看ACER怎样？因为CEO买了一百万美金的股票暴涨了。
 
Volvofun 说:
看看ACER怎样？因为CEO买了一百万美金的股票暴涨了。
点击展开...
With a quick look at it, ACER seems to be a good stock to have some: with PDUFA day on upcoming 12 January to look forward to, and relatively low market cap of around $65 million at a price of $3.33 a piece of share.

Exercise of some caution though, since CEO bought ($1.15 - $1.20 per share), the price has been up to today's $3.33; The deal of CEO and Chair's injection of cash looks like a bridge financing for December, so do expect a major financing may be forthcoming; the underlining indication is a rare disease which may only have limited market; and this one is strange without the usual bears. It gets almost universal appraise?

All in all, the stock price would be at least multiple fold higher if its ACER-001 is approved on or before 15 Jan. All are JMO, please do your own DD.
 
最后编辑:
GlobeCitizen 说:
With a quick look at it, ACER seems to be a good stock to have some: with PDUFA day on upcoming 12 January to look forward to, and relatively low market cap of around $65 million at a price of $3.33 a piece of share.

Exercise of some caution though, since CEO bought ($1.15 - $1.20 per share), the price has been up to today's $3.33; The deal of CEO and Chair's injection of cash looks like a bridge financing for December, so do expect a major financing may be forthcoming; the underlining indication is a rare disease which may only have limited market; and this one is strange without the usual bears. It gets almost universal appraise?

All in all, the stock price would be at least multiple fold higher if its ACER-001 is approved on or before 15 Jan. All are JMO, please do your own DD.
点击展开...
I bought some just below 2.0 and sold it at 3.2. I thought it was kind of effort of the CEO to support the stock. Nothing serious has happened. Therefore, I left. But if it pulls back，I will jump in again.
 
Volvofun 说:
I bought some just below 2.0 and sold it at 3.2. I thought it was kind of effort of the CEO to support the stock. Nothing serious has happened. Therefore, I left. But if it pulls back，I will jump in again.
点击展开...
Good for you. In the small biotech world, anything could happen. In anticipation of next month's approval and with low mc, the price may continue heading north, but if a financing deal arrives with unfavorable term deemed by the market, then the price may drop.
 
GlobeCitizen 说:
Good for you. In the small biotech world, anything could happen. In anticipation of next month's approval and with low mc, the price may continue heading north, but if a financing deal arrives with unfavorable term deemed by the market, then the price may drop.
点击展开...
Not bad. Another reason was I did not feel great about the market. Therefore, any popup is a good opportunity to cash in.
 
Volvofun 说:
Not bad. Another reason was I did not feel great about the market. Therefore, any popup is a good opportunity to cash in.
点击展开...
did a quick calculation on ACER: a target price of about $7.8, equivalent to about 136% increase when ACER-001 approved, compared to a target price of about $6 when DCVax-L approved which would be a 590% increase. Those numbers don't include potential with other indications, and the irrational market reaction. ACER is close to RA action while NWBO still has not yet submited BLA.

[These are just for initial stage. Considering the potential, NWBO would be unmatched due to MOA which can readily apply to many other solid cancers, operable and inoperable, and most importantly due to the huge potentials for combo treatment]

1671460175304.png
 
最后编辑:
Voted this morning with the shares our family have, all along with Board recommendations except Item 4 of executive compensation which we voted against. Strangely though, more than one half of our shares were unaccountable for voting. Called brokers, they were able to account for all shares we have, so the problem is with Geogeson who receives votes on behalf of Northwest Bio. From the end of Geogeson, it just cannot locate all the shares we have.

No biggie though, may not deserve the efforts to locate all missing shares to vote. I am going to contact the company to let them know this problem.
 
您必须登录或注册才可回复。
后退
顶部